Kyverna Therapeutics, Inc Common Stock

Kyverna Therapeutics, Inc Common Stock

Yahoo Finance • 7 days ago

Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond

Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middle East and concerns about AI disruption... Full story

Yahoo Finance • 3 months ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel t... Full story

Yahoo Finance • 3 months ago

Kyverna rises on new mid-stage trial data for myasthenia gravis therapy

[Myasthenia gravis is shown using the text] Andrii Dodonov Shares of Kyverna Therapeutics (KYTX [https://seekingalpha.com/symbol/KYTX]) rose on Monday after the company announced long-term follow-up data from a pivotal trial for its lead... Full story

Yahoo Finance • 3 months ago

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story

Yahoo Finance • 3 months ago

The Oncology Institute Names Minh Merchant Chief Legal Officer

TOI Management, LLC CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joine... Full story

Yahoo Finance • 4 months ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) EMERYVILLE, Calif., March... Full story

Yahoo Finance • 7 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 7 months ago

Biggest stock movers Tuesday: RILY, ORGO, KYTX, RC, LWLG and more

[Stock Market] sweetym/iStock via Getty Images U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's big... Full story

Yahoo Finance • 8 months ago

Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04

* Kyverna Therapeutics press release [https://seekingalpha.com/pr/20305094-kyverna-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial] (KYTX [https://seekingalpha.com/symbol/KYTX]): Q3 GAAP EPS of -$0.85 misse... Full story

Yahoo Finance • 8 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data in generalized myast... Full story

Yahoo Finance • 9 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG... Full story

Yahoo Finance • 9 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consiste... Full story

Yahoo Finance • 9 months ago

Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from $24, while maintaining a... Full story

Yahoo Finance • 9 months ago

KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on beha... Full story

Yahoo Finance • 10 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable sa... Full story

Yahoo Finance • 10 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​ Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif.,... Full story

Yahoo Finance • 11 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis suppo... Full story

Yahoo Finance • 11 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that... Full story

Yahoo Finance • 11 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to in... Full story

Yahoo Finance • last year

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stoc... Full story